The advent of immunosuppressive drugs has produced great advances in the fields of transplantation immunology and cancer chemotherapy. However, the numerous benefits provided by these agents have been accompanied by an increased incidence of infection among patients receiving immunosuppressive therapy (7) . Various microorganisms, including bacteria (18) , fungi (8, 10) , and viruses (6, 19) , have been isolated from such infections, with the lungs appearing to be the major target organ.
An increased susceptibility to infection implies some alteration in the immune mechanisms of the host. The possibility that this alteration is single in nature seems remote; rather, a multitude of factors, both humoral and cellular, are probably involved.
Previous studies in this laboratory revealed that immunosuppression with cyclophosphamide (Cytoxan; Mead Johnson Laboratories, Evansville, Ind.) caused a decrease in the serum yglobulin level (in preparation). Similar data were reported by Mackiewicz (15) . The high incidence of lung involvement in the patient receiving immunosuppressants suggests a possible involvement of the reticuloendothelial (RE) system and the phagocytic process.
This study was designed to determine the effect of immunosuppressive therapy on RE and renal function in an effort to help explain the increased susceptibility to infection. MATERIALS (2, 4) . In light of this, the present study deals with renal, as well as hepatic, alveolar, and splenic tissue.
Since this study was not designed to measure the kinetics of bacterial clearance and killing, the time period of 1 hr was utilized. This allowed for maximal uptake of bacteria and ample time for the process of intracellular killing to be initiated.
Statistical analysis. Statistical analysis consisted of the standard T-test using unpaired analysis, with a P value 0.05 being considered significant.
RESULTS
Side effects related to drug therapy. A summary of the various side effects observed in drugtreated animals is given in Table 1 . In addition to the expected leukopenia, there was a marked degree of petechial hemorrhage in both the lungs and the small bowel. Among animals receiving the maximal dosage (100 mg/kg) there was a high incidence of hemorrhagic cystitis, hematuria, and acute diarrhea. The severity and frequency of these side effects appeared to be directly related to the dose of drug employed.
The loss in total body weight, as well as loss in the relative weight of the spleen, were observed to be dose dependent also ( Table 2 ). The average body weight of untreated animals was 212 g, whereas animals receiving 100 mg/kg of cyclophosphamide suffered a 25% decrease in total body weight. Splenic atrophy was observed in all animals, regardless of the dose regimen employed. Spleens from nontreated animals weighed approximately 0.24% of the total body weight. The highest dose of cyclophosphamide caused as much as a 50% decrease in this figure. In contrast, the liver, lungs, and kidneys showed a significant increase in their relative weights at the maximal dosage employed.
Effect of drug therapy on bacterial ingestion. The results of experiments designed to test the ability of the RE system of treated animals to ingest labeled pseudomonas are shown in Table  3 . Using the percentage of injected label recovered by the individual organs as a measure of ingestion, the liver, lungs, and kidneys were observed to exhibit no significant change in their ability to Decrease in bactericidal ability with drug therapy. The results of assays of the bactericidal ability of the liver, spleen, lungs, and kidneys from Cytoxan-treated animals are shown in Tables 7 and 8 . Injected staphylococci appeared to be more resistant than pseudomonas to inactivation. The liver, spleen, and lungs achieved 61%, 55%, and 62% kill respectively, whereas the kidneys achieved 94% kill. More than 89% of ingested pseudomonas were killed after 1 hr in all organs measured. There was no change in the ability of either the liver or the spleen from treated animals to kill the ingested microorganisms, regardless of the drug dose or the bacterium employed. In contrast, a marked decrease in bactericidal effect was observed in both the lung and the kidneys, and the degree of impairment increased with the dosage. The lungs and kidneys of untreated animals were capable of killing more than 96% of ingested pseudomonas; drug therapy of 50 and 100 mg/kg decreased this value to 84% and 65%, respectively, in the lung and to 78 % and 73 % in the kidney.
Staphylocidal capability was reduced from 62 % in the lungs of untreated animals to 20% in the lungs of animals receiving 100 mg/kg of cyclophosphamide. The kidneys of treated animals showed a similar decrease in their staphylocidal effect; animals receiving 100 mg/kg exhibited 80% kill compared to 94% in controls. DISCUSSION High dose immunosuppressive therapy with cyclophosphamide was accompanied by a number of side effects, including leukopenia and petechial hemorrhage in the lungs and small bowel. Acute (21) and are attributed to drug toxicity. Treatment of mice with either cyclophosphamide or cortisone incurred a marked loss of splenic tissue, with the liver and kidneys remaining virtually unchanged (5, 14) . Our studies in rats have revealed similar findings; doses as low as 25 mg/kg caused a significant decrease in splenic weight. This is undoubtedly a result of the severe lymphoid injury (1) caused by cyclophosphamide and other immunosuppressive drugs. The fact that high-dose therapy (100 mg/kg) caused an increase in the relative weight of the liver, lung, and kidney is actually a reflection of a loss of total body weight, since these three organs exhibited no significant change in their actual weights, regardless of the treatment regimen employed.
The results of experiments to assess the RE ingestive powers of animals treated with cyclophosphamide varied depending upon the bacterium employed. With the exception of the spleen at the highest dose level, there was no significant difference in the amount of labeled pseudomonas recovered, regardless of the organ or the dose level used. The liver proved to have a greater phagocytic capacity than any of the other organs examined. The spleen exhibited the next greatest uptake. A small amount (1 %) was recovered by the lungs and only traces were found in the kidneys. Others have reported similar results (3, 11, 14, 20 (13) . In contrast, high-dose drug therapy significantly impaired the spleen's ability to remove staphylococci from the blood. Earlier experiments in this laboratory showed that cyclophosphamide produced a significant decrease in the levels of serum y-globulin (in preparation). However, the fact that impairment of normal phagocytic function in the liver, lungs, and kidneys was not observed indicated that lack of sufficient serum opsonins was probably not the cause of this reduced staphylococcal uptake by the spleen. Additional work will be required to resolve this problem.
High dose immunosuppression was not observed to cause any deficiency in the ability of the RE system to ingest pseudomonas. However, a striking decrease in the ability of the lungs and kidneys to kill this bacterium was noted. Similar results involving staphylocidal ability were obtained, although this organism was apparently not as susceptible to degradation as was pseudomonas. The liver, spleen, and lungs of nontreated controls all revealed less than 65% kill of ingested staphylococci, whereas the kidneys displayed a very rapid rate of destruction with over 93% kill. The initial destruction rates of pseudomonas in control animals were more uniform, with greater than 90% of the ingested bacteria being killed, regardless of the organ involved. The sharp decrease in this initial rate of destruction by the kidneys observed in treated animals could possibly lead to the development of a bacteremia (9) . This, in conjunction with the decreased bactericidal capacity of the lungs, could well lead to systemic infection coupled with pulmonary or renal involvement, or both.
The possibility that the decreased bactericidal activity observed in the kidneys of treated animals is related to the drug-induced leukopenia must be considered. Were this the case, one would expect the apparent ingestion of bacteria by this organ to also be impaired. However (12) . We observed no significant change in the ingestive powers of the lungs from treated animals. It seems logical to assume, therefore, that this apparent defect in the ability of the lungs to inactivate ingested bacteria lies, not in its ingestive powers, but in its ability to kill the bacteria once they have been ingested. Cyclophosphamide was recently shown to induce a significant decrease in the levels of fibrinolytic and proteolytic enzymes of the leukocyte (17) . If the hydrolytic enzymes involved in intracellular degradation are also so affected, a sharp decrease in bactericidal powers would be expected. A closely allied possibility is that interaction between the phagocytic membranes and lysosomes of phagocytizing cells is hindered in some manner, thus preventing release of lysosomal enzymes necessary for bacterial inactivation. It is quite possible that intracellular degradation within the liver and spleen is unaffected by drug treatment because of the relatively greater number of phagocytic cells found in these two organs compared to the number contained in alveolar and renal tissue. Thus, drug therapy may cause severe damage to the few phagocytic cells present in the lung and kidney, whereas the liver and spleen may possess such an abundance of phagocytic cells that drug damage to these organs is less apparent. Studies involving long-term destruction rates of bacteria by the RE system are in progress in an effort to establish the validity of this hypothesis.
A third possible cause for this reduction in the bactericidal powers of the lung lies in the fact that hypoxia is known to produce lysosomal disintegration. The acute degree of pulmonary hemorrhage caused by cyclophosphamide therapy may well cause a decrease in blood flow through the lung. The resulting hypoxia might reduce the lysosomal arsenal, consequently reducing the bactericidal ability of the organ.
